Skip to main content

Fortress Biotech, Inc. (FBIO)

NASDAQ: FBIO · IEX Real-Time Price · USD
3.03
-0.05 (-1.62%)
After-hours:Oct 15, 2021 7:11 PM EDT
3.08
0.00 (0.00%)
At close: Oct 15, 4:00 PM
Market Cap311.27M
Revenue (ttm)52.65M
Net Income (ttm)-33.20M
Shares Out80.96M
EPS (ttm)-0.42
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume387,236
Open3.12
Previous Close3.08
Day's Range3.05 - 3.13
52-Week Range2.12 - 6.10
Beta2.40
AnalystsStrong Buy
Price Target10.17 (+230.2%)
Est. Earnings DateNov 8, 2021

About FBIO

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intra...

IndustryBiotechnology
Founded2006
CEOLindsay Rosenwald
Employees111
Stock ExchangeNASDAQ
Ticker SymbolFBIO
Full Company Profile

Financial Performance

In 2020, FBIO's revenue was $45.60 million, an increase of 24.49% compared to the previous year's $36.63 million. Losses were -$46.53 million, 16.4% more than in 2019.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for FBIO stock is "Strong Buy." The 12-month stock price forecast is 10.17, which is an increase of 230.19% from the latest price.

Price Target
$10.17
(230.19% upside)
Analyst Consensus: Strong Buy

News

Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented...

NEW YORK and SOLANA BEACH, Calif., Oct. 13, 2021 /PRNewswire/ -- Cyprium Therapeutics, Inc. ("Cyprium"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") partner company, with support from its licen...

3 days ago - PRNewsWire

Fortress' (FBIO) Partner Meets Study Goal for Menkes Disease

Cyprium Therapeutics, a partner company of Fortress Biotech (FBIO), reports positive data from two pivotal studies evaluating CUTX-101 in patients with Menkes disease.

5 days ago - Zacks Investment Research

Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented...

Cyprium Therapeutics, a partner company of Fortress Biotech, is developing CUTX-101 for the treatment of Menkes disease

1 week ago - GlobeNewsWire

Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca

Triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech 1

1 week ago - GlobeNewsWire

Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial Officer

NEW YORK and SCOTTSDALE, Ariz., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”) focused on iden...

1 week ago - GlobeNewsWire

Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences,...

Option exercise triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech 1

2 weeks ago - GlobeNewsWire

Fortress Biotech to Participate in Three September 2021 Investor Conferences

NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizin...

1 month ago - GlobeNewsWire

Fortress Biotech (FBIO) Reports Q2 Loss, Tops Revenue Estimates

Fortress Biotech (FBIO) delivered earnings and revenue surprises of 71.43% and 29.11%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Fortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate Highlights

Net revenue for second quarter of 2021 increased 89% year-over-year to $17.8 million, a quarterly record

2 months ago - GlobeNewsWire

Fortress Biotech (FBIO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Why Fortress Biotech Stock Is Sinking Today

The FDA refused to approve IV tramadol for the second time.

4 months ago - The Motley Fool

Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts

Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks, N...

Other symbols:CYTRMBIOMEIPMTNBORPH
4 months ago - PennyStocks

Biotech Penny Stocks To Watch For June 2021

These penny stocks are expecting to release key information this month. The post Biotech Penny Stocks To Watch For June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...

Other symbols:APTOMBIORGLS
4 months ago - PennyStocks

Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Ra...

The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzi...

4 months ago - Benzinga

Fortress Biotech to Participate in Three June 2021 Virtual Investor Conferences

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing...

4 months ago - GlobeNewsWire

REPEAT -- Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021

4 months ago - GlobeNewsWire

Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021

5 months ago - GlobeNewsWire

4 Biotech Stocks Set to Outpace Q1 Earnings Estimates

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

Other symbols:AVROBYSIXAIR
5 months ago - Zacks Investment Research

Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Eu...

Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic kidney d...

5 months ago - GlobeNewsWire

Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

5 months ago - Zacks Investment Research

3 Penny Stocks That Wall Street Wants You To Buy Now

Penny stocks are very risky, which is why they have such low prices. Many of the companies in this risky part of the market will go bankrupt.

Other symbols:ABEOSYBX
5 months ago - Benzinga

7 Penny Stocks That May Not Be Penny Stocks For Long

Many penny stocks are destined for bankruptcy, but there are some that will survive. Wall Street thinks these companies are undervalued.

5 months ago - InvestorPlace

Why Fortress Biotech Stock Is Sinking Today

Investors were not thrilled with the company's latest regulatory update.

6 months ago - The Motley Fool

Is the Options Market Predicting a Spike in Fortress Biotech (FBIO) Stock?

Investors need to pay close attention to Fortress Biotech (FBIO) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

Fortress Biotech (FBIO) Surges 11.5%: Is This an Indication of Further Gains?

Fortress Biotech (FBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre...

6 months ago - Zacks Investment Research